Tahlia Scheinberg, Rhiannon Mellor, Arun A Azad, Paul Bonnitcha, James Buteau, Ian D Davis, Louise Emmett, Michael Fitzpatrick, Roslyn J Francis, Rachel MN Kim, Edmond Kwan, Hui-Ming Lin, Andrew J Martin, Peter J Meikle, Andrew M Scott, Martin Stockler, Alexander W Wyatt, Michael S Hofman, Lisa G Horvath for the TheraP trial investigators on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
Rhiannon Mellor, Michael Fitzpatrick, Tahlia Scheinberg, Rachel MN Kim, Paul Bonnitcha, David Sullivan, Hui-Ming Lin, Ian D Davis, Andrew J Martin, Peter J Meikle, Anthony Joshua, Margaret McJannett, Vinod Subhash, Sonia Yip, Scott A North, Raymond S McDermott, Kim N. Chi, Martin R Stockler, Christopher Sweeney, Lisa G Horvath for the ENZAMET trial investigators on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Megan Crumbaker, Santosh Gupta, Nathan Papa, Nadine Hartmann, Rick Wenstrup, Shahneen Sandhu, Anthony M. Joshua, Shalini Subramaniam, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J Francis, Jeffrey C. Goh, Sonia Yip, Vinod Subhash, Hayley Thomas, Michael S Hofman, Martin R Stockler, Ian D Davis, Louise Emmett, on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
A. Weickhardt, F. Foroudi, N. Lawrentschuk, J. Xie, Y. Ko, M. Sidhom, A. Pal, P. Grimison, A. Zhang, S. Ng, C. Tang, E. Hovey, C. Chen, G. Hruby, A. Guminski, S.R.Oakes, C. Conduit, B. Tran, I.D Davis, D.Hayne on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
Lisa G Horvath, Hui-Ming Lin, Ian D Davis, Andrew J Martin, Nicole Yeung, Rachel MN Kim, Neil Portman, Anthony Joshua, Margaret McJannett, Vinod Subhash, Sonia Yip, Scott A North, Raymond S McDermott, Kim N Chi, Martin R Stockler, Christopher Sweeney for the ENZAMET trial investigators on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
Z Sabahi, N Papa, W P. Fendler, A Nguyen, K Wong, N Ayati, B Ho, J Chen, T Cusick, I A. Burger, M Crumbaker, G Marx, S Sharma, M Frydenberg, S Sandhu, I D. Davis, M R. Stockler, C Sweeney,
A M. Joshua, L Emmett, The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
Alison Y. Zhang, Ian D. Davis, Hayley Thomas, Ronan Andrew McLaughlin, Thean Hsiang Tan, David William Pook, Gavin M. Marx, Robert Richard Zielinski, Shahneen Sandhu, Alastair Thomson, M. Neil Reaume, Scott A. North, John McCaffrey, Raymond S. McDermott, Nicola Jane Lawrence, Lisa Horvath, Simon Chowdhury, Kim N. Chi, Martin R. Stockler, Christopher Sweeney
Predictive and prognostic value of baseline PSMA-PET total tumor volume (TTV) and SUVmean within a randomised phase 2 trial of enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901)
ENZA-p
ASCO 2025
03/06/2025
Louise Emmett
Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177Lu-PSMA-617 or cabazitaxel: an exploratory post-hoc analysis of a randomized phase II trial
